J2Hbiotech, 제이투에이치바이오텍

Change the world

J2HBiotech - Journey to Healthcare Solutions

R&D Center (Suwon)

R&D Center

B-209~210,212 / B2-210~212
142-10, Saneop-ro 156beon-gil, Gwonseon-gu, Suwon-si, Republic of Korea

Departments

Medicinal
Chemistry
Analysis
Pharmacology
Non-clinical
Clinical research
Business
development

Platform Technology

OPTIFLEX ^®

OPTIFLEX facilitates the new drug candidate discovery utilizing the multidimensional scoring system that evaluates and optimizes the physiochemical and pharmacokinetic properties to accelerate the derivation of the novel drug candidates

Platform Technology

PROTACTICS ^®

PROTACTICS uses E3 ligase binder-linker conjugate library to quickly and efficiently synthesize new targeted protein degradation drug candidates through optimization

Platform Technology

Evolution of R&D Center

2022MASH drug candidate (J2H-1702) entered phase 2 clinical trial
Selected as a Korea Drug Development Fund’s funding project (4th generation treatment for NSCLC)
2021Established clinical research team
2020MASH Drug Candidate (J2H-1702) entered phase 1 clinical trial
Designated as the excellent corporation R&D center (Ministry of Science and ICT)
2019Selected as a Korea Drug Development Fund’s funding project (Treatment for multiple sclerosis)
Established pharmacology team & lab
Three on-going IND-enabling stage projects
Early-stage licensing out of two projects (China, Korea)
2017Established R&D Center (Suwon Venture Valley II)
Selected as a Ministry of Health and Welfare’s funding project (Antiviral drug)
Won patent lawsuit against 11 pharmaceutical companies
2016Established synthesis/analysis lab
Developed new drug discovery platform
2015Certified as Company Affiliated Research Institute (Korea Industrial Technology Association)
Initiated new drug discovery research

Patent

Patent application (Korea)

Patent application (Korea): 35cases

Patent registration (Korea)

Patent registration (Korea): 10cases

PCT application (Korea)

PCT application (Korea): 23cases

International patents

International patents: 29cases

R&D Pipeline

Pipeline	Type	Target Disease	R&D Stage
Pipeline	Type	Target Disease	Discovery	Animal POC	Preclinical	Phase 1	Phase 2
J2H-1702	Small molecule	Metabolic dysfunction- associated steatohepatitis	50% Detail View
			J2H-1702, a selective 11β-HSD1 enzyme inhibitor, is an orally administered small molecule drug candidate that has demonstrated significant improvement in both hepatic steatosis and liver fibrosis, as well as improvement in liver function and dyslipidemia, in various animal models of MASH. Phase 1 clinical trials have demonstrated a favorable safety and pharmacokinetic profile, and Phase 2 clinical trials are underway for the treatment of patients with metabolic dysfunction-associated steatohepatitis (MASH) beginning in 2022
J2H-1801	Small molecule	Multiple sclerosis	50% Detail View
			J2H-1801 is a hybrid new drug candidate that overcomes the limitations of the current MS treatment Tecfidera (Biogen, USA) by significantly reducing the side effects (GI issues, flushing) while maintaining equivalent efficacy. Orally administered J2H-1802 is metabolized to monomethyl fumarate (MMF), an active metabolite of Tecfidera, and is specifically designed to mitigate the side effects while eliminating non-hazardous components from the body.
J2H-2002	TPD	Non-small cell lung cancer	50% Detail View
			J2H-2002 is a targeted protein degradation (TPD) drug candidate for the treatment of non-small cell lung cancer (NSCLC) targeting mutant epidermal growth factor (EGFR). J2H-2002 is a next-generation oral NSCLC drug candidate effective for treating patients who developed resistance to previous treatment methods, and it simultaneously reduces the risk of developing further drug resistance.
J2H-2201	TPD	Non-small cell lung cancer	50%
J2H-2104	Small molecule	Solid tumor	50%
J2H-2103	TPD	Solid tumor	50%
J2H-2202	TPD	Non-small cell lung cancer	50%

* TPD: Targeted protein degradation

R&D Network

Domestic Partners

Global Partners

Collaborative R&D